Trafalgar International (GCAN) EBIT Growth (1y) (2018 - 2026)
Trafalgar International (GCAN) EBIT Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.34% |
| Dec 31, 2025 | -43.01% |
| Sep 30, 2025 | 7.49% |
| Jun 30, 2025 | -22.91% |
| Mar 31, 2025 | -11.77% |
| Dec 31, 2024 | 14.54% |
| Sep 30, 2024 | 19.86% |
| Jun 30, 2024 | 5.19% |
| Mar 31, 2024 | 1.31% |
| Dec 31, 2023 | -4.16% |
| Sep 30, 2023 | -2.35% |
| Jun 30, 2023 | 3.79% |
| Mar 31, 2023 | 6.98% |
| Dec 31, 2022 | 64.81% |
| Sep 30, 2022 | 33.68% |
| Jun 30, 2022 | 31.12% |
| Mar 31, 2022 | 50.80% |
| Dec 31, 2021 | -124.36% |
| Sep 30, 2021 | -4.81% |
| Jun 30, 2021 | 23.72% |